ID   A375-VR [2015]
AC   CVCL_AQ00
DR   cancercelllines; CVCL_AQ00
DR   Wikidata; Q54606866
RX   PubMed=26497853;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0132 ! A-375
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 02-05-16; Last updated: 05-10-23; Version: 14
//
RX   PubMed=26497853; DOI=10.18632/oncotarget.5755;
RA   Fofaria N.M., Frederick D.T., Sullivan R.J., Flaherty K.T.,
RA   Srivastava S.K.;
RT   "Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors
RT   alone and in combination with MEK1/2 inhibitors in melanoma.";
RL   Oncotarget 6:40535-40556(2015).
//